Type 2 Diabetes Mellitus Treatment Market Size, Share & Trends Analysis Report By Drug Class (Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists), By Route of Administration (Oral, IV), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 203

Type 2 Diabetes Mellitus Treatment Market Size, Share & Trends Analysis Report By Drug Class (Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists), By Route of Administration (Oral, IV), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030

Type 2 Diabetes Mellitus Treatment Market Growth & Trends

The global type 2 diabetes mellitus treatment market size is anticipated to reach USD 91.9 billion by 2030, growing at a CAGR of 6.9% from 2024 to 2030, according to a report by Grand View Research, Inc. This expansion is driven by the increasing global burden of type 2 diabetes and advancements in treatment options. As lifestyle changes, such as poor dietary habits and physical inactivity, contribute to higher obesity rates, the incidence of type 2 diabetes is on the rise. According to the International Diabetes Federation (IDF), over 500 million people worldwide are affected by diabetes, with Type 2 diabetes accounting for approximately 90% of these cases. This growing patient population fuels demand for effective and innovative treatments.

Advancements in diabetes management are boosting market growth. The development of new classes of medications, such as GLP-1 receptor agonists and SGLT2 inhibitors, has significantly improved treatment outcomes. These therapies not only lower blood glucose levels but also offer additional benefits like cardiovascular protection and weight management. The introduction of novel insulin formulations and technologies, including continuous glucose monitors and insulin pumps, further enhances patient care and drives market expansion. For instance, in January 2023, the Food and Drug Administration (FDA) approved Novo Nordisk’s diabetes medication, Rybelsus, as a first-line treatment for lowering blood sugar levels. With this approval, individuals with Type 2 diabetes, in collaboration with their healthcare providers, can now incorporate Rybelsus early in their treatment plan, offering a new option for managing their condition from the onset.

In addition, increasing healthcare investments and improved access to diabetes care contribute to market growth. Governments and healthcare organizations are investing in diabetes management programs, public awareness campaigns, and healthcare infrastructure improvements. These efforts aim to enhance early diagnosis, treatment adherence, and overall patient management.

Type 2 Diabetes Mellitus Treatment Market Report Highlights

• In 2023, the insulin segment accounted for the largest revenue share of 32.8% in diabetes mellitus, type 2 treatment market. This growth primarily is attributed to the rising prevalence of type 2 diabetes around the world due to sedentary lifestyle
• Subcutaneous are anticipated to achieve the highest CAGR of 9.4% in the diabetes mellitus, type 2 treatment market during the forecast period
• The retail pharmacies segment accounted for the largest revenue share of around 70.0% in diabetes mellitus, type 2 treatment market in 2023

Please note The report will be delivered in 4-8 business days upon order notification.